Cullinan Oncology Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
CGEM Nasdaq 8731 https://www.cullinanoncology.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cullinan Oncology Inc

Cullinan Oncology to Participate in the Guggenheim 5th Annual Oncology Conference and the SVB Securities Global Biopharma Conference - Feb 2nd, 2023 9:01 pm
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb 1st, 2023 9:42 pm
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, a Novel T-Cell Engager for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma - Jan 24th, 2023 1:00 pm
12 Most Undervalued Pharma Stocks To Buy According To Hedge Funds - Jan 23rd, 2023 4:07 pm
11 Cheap Value Stocks to Buy According to Seth Klarman - Dec 29th, 2022 3:31 am
Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2022 Financial Results - Nov 14th, 2022 12:00 pm
Cullinan Oncology Announces the Appointment of David P. Ryan, M.D. to its Board of Directors - Nov 2nd, 2022 12:00 pm
Cullinan Oncology to Participate in Upcoming Investor Conferences - Nov 1st, 2022 11:00 am
Cullinan Oncology Significantly Increases Ownership Stake in its MICA Subsidiary which Holds Worldwide Rights to Clinical-Stage Novel Monoclonal Antibody CLN-619 - Oct 25th, 2022 11:00 am
Cullinan Oncology to Participate in the HC Wainwright Global Investment Conference and the Morgan Stanley Healthcare Conference - Sep 7th, 2022 12:00 pm
Cullinan Oncology Announces Appointment of Jacquelyn Sumer as Chief Legal Officer - Aug 15th, 2022 8:57 pm
Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2022 Financial Results - Aug 10th, 2022 11:00 am
Cullinan Oncology to Participate in BTIG Biotechnology Conference and Canaccord Growth Conference - Aug 1st, 2022 12:00 pm
Cullinan Oncology to Participate in William Blair Biotech Focus Conference - Jul 5th, 2022 8:01 pm
Cullinan Oncology and Taiho Pharmaceutical Complete Agreement for Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417 - Jun 23rd, 2022 12:00 pm
Cullinan Oncology to Present Updated Data Demonstrating the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20 Insertion Mutation Positive Non-Small Cell Lung Cancer at the 2022 ASCO Annual Meeting - May 31st, 2022 12:00 pm
Cullinan Oncology to Host Analyst and Investor Briefing at 2022 ASCO Annual Meeting - May 26th, 2022 12:45 pm
Cullinan Oncology to Present at H.C. Wainwright Global Investment Conference - May 19th, 2022 12:00 pm
Cullinan Oncology Provides Corporate Update and Reports First Quarter 2022 Financial Results - May 16th, 2022 10:45 am
Why Are Cullinan Oncology Shares Rising Today? - May 12th, 2022 3:18 pm